Abstract
In a phase I trail, 2,3-dihydro-1H-imidazo[1,2-b]pyrazole was administered iv weekly at doses ranging from 0.1 to 3.0 g/m2/wk to patients with refractory metastatic solid tumors. Although gastrointestinal toxicity was tolerable and neither granulocyte nor platelet toxicity was seen, significant dose-limiting hemolysis was encountered at doses of 1.5 g/m2/wk. While no definite tumor regressions were seen in the 32 patients evaluable for response, two patients (squamous cell carcinoma of lung and tonsil) had clinically useful improvement.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1153-1156 |
| Number of pages | 4 |
| Journal | Cancer Treatment Reports |
| Volume | 64 |
| Issue number | 10-11 |
| State | Published - Dec 1 1980 |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint Dive into the research topics of 'Phase I clinical trial of weekly iv 2,3-dihydro-1H-imidazo[1,2-b]pyrazole (IMPY)'. Together they form a unique fingerprint.
Cite this
Vogel, C. L., Denefrio, J. M., Padgett, L. C., & Silverman, M. A. (1980). Phase I clinical trial of weekly iv 2,3-dihydro-1H-imidazo[1,2-b]pyrazole (IMPY). Cancer Treatment Reports, 64(10-11), 1153-1156.